<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04435925</url>
  </required_header>
  <id_info>
    <org_study_id>UNUD-CTR-FK110620-001</org_study_id>
    <nct_id>NCT04435925</nct_id>
  </id_info>
  <brief_title>Inflammatory Effect Comparison Between Fentanyl and Remifentanil in Mastectomy Under General Anesthesia</brief_title>
  <official_title>Inflammatory Effect Comparison Between Fentanyl and Remifentanil in Mastectomy Under General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Udayana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Udayana University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mastectomy triggers stress and inflammation responses due to tissue trauma. Surgical stress&#xD;
      will increase levels of hormones (adrenocorticotropic hormone, cortisol, antidiuretic&#xD;
      hormone, epinephrine, norepinephrine, and dopamine) and inflammatory cytokines (Tumor&#xD;
      Necrotic Factor-α, interleukin-1, interleukin-2, and interleukin-6) in the body. This causes&#xD;
      insulin resistance, gluconeogenesis, and glycolysis, and impaired insulin secretion, which&#xD;
      results in hyperglycemia due to intraoperative stress. Intraoperative hyperglycemia increases&#xD;
      postoperative complications and mortality. Inhibition of hyperglycemia due to operative&#xD;
      stress and stress hormones with good anesthetic management in improving patient outcomes.&#xD;
&#xD;
      The choice of opioid type plays an important role in suppressing the perioperative stress and&#xD;
      inflammatory response. Opioids are an alternative, besides the use of regional anesthetic&#xD;
      techniques which have been proven to suppress the perioperative stress response. Fentanyl is&#xD;
      one of the phenylpiperidine synthetic opioids. Large doses of fentanyl can reduce stress&#xD;
      responses but also increase side effects, such as hemodynamic instability and decrease T-cell&#xD;
      function.&#xD;
&#xD;
      Remifentanil provides unique pharmacokinetic benefits through nonspecific esterase enzyme&#xD;
      metabolism, so it has a very fast onset and half-life. In addition, remifentanil also&#xD;
      provides benefits in reducing the production of interleukin 6 cytokines (IL-6) and tumor&#xD;
      necrosis factor α (TNF-α) and inhibits neutrophil migration through the endothelial layer.&#xD;
&#xD;
      The stress response to stress and inflammation is directly proportional to the dose of&#xD;
      remifentanil given. It is reported that remifentanil can suppress cortisol response according&#xD;
      to increasing dose.&#xD;
&#xD;
      Winterhalter et al. and Lee et al. reported that remifentanil is better at suppressing the&#xD;
      stress response than fentanyl. On the other hand, Bell et al. showed no difference in&#xD;
      cortisol and hemodynamic levels between the two groups.&#xD;
&#xD;
      The goal of this study is to see if remifentanil provides less increase in serum epinephrine&#xD;
      level, norepinephrine level, platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio&#xD;
      (LMR), and blood glucose level at one-hour and 24-hours postoperative in patients undergoing&#xD;
      mastectomy surgery under general anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 27, 2020</start_date>
  <completion_date type="Actual">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a single-blind, randomized control trial. It provides a controlled treatment of general anesthesia with an opioid regimen between remifentanil and fentanyl.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The opioid selection disguised to the patient. Eligible subjects will be randomized so that each research subject has the same opportunity to be included in both groups.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Epinephrine</measure>
    <time_frame>1-hour (postoperative)</time_frame>
    <description>Serum epinephrine level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Epinephrine</measure>
    <time_frame>24-hours (postoperative)</time_frame>
    <description>Serum epinephrine level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Norepinephrine</measure>
    <time_frame>1-hour (postoperative)</time_frame>
    <description>Serum norepinephrine level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Norepinephrine</measure>
    <time_frame>24-hours (postoperative)</time_frame>
    <description>Serum norepinephrine level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PLR</measure>
    <time_frame>1-hour (postoperative)</time_frame>
    <description>platelet-to-lymphocyte ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PLR</measure>
    <time_frame>24-hours (postoperative)</time_frame>
    <description>platelet-to-lymphocyte ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LMR</measure>
    <time_frame>1-hour (postoperative)</time_frame>
    <description>lymphocyte-to-monocyte ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LMR</measure>
    <time_frame>24-hours (postoperative)</time_frame>
    <description>lymphocyte-to-monocyte ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose</measure>
    <time_frame>1-hour (postoperative)</time_frame>
    <description>serum glucose level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose</measure>
    <time_frame>24-hours (postoperative)</time_frame>
    <description>serum glucose level</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Breast Disease</condition>
  <condition>Anesthesia</condition>
  <condition>Inflammatory Response</condition>
  <arm_group>
    <arm_group_label>Remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to this group will receive IV Remifentanil as an opioid for general anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients assigned to this group will receive IV Fentanyl as an opioid for general anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Loading dose: 0.5 mcg/kg Maintenance dose: 1 mcg/kg/minute</description>
    <arm_group_label>Remifentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Loading dose: 2 mcg/kg Maintenance dose: 0.4 mcg/kg/30-minutes</description>
    <arm_group_label>Fentanyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for a mastectomy under general anesthesia&#xD;
&#xD;
          -  Patients aged 30-65 years old&#xD;
&#xD;
          -  ASA physical status: I-II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to be included in the study&#xD;
&#xD;
          -  History of opioid allergies&#xD;
&#xD;
          -  Long-term use of steroids&#xD;
&#xD;
          -  Patients on β blockers medication&#xD;
&#xD;
          -  History of diabetes, autoimmune disease, or heart disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>I Gusti AG Hartawan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Udayana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanglah General Hospital</name>
      <address>
        <city>Denpasar</city>
        <state>Bali</state>
        <zip>80114</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <last_update_submitted>May 30, 2021</last_update_submitted>
  <last_update_submitted_qc>May 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Udayana University</investigator_affiliation>
    <investigator_full_name>Christopher Ryalino</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

